Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 29;54(3):263-271.
doi: 10.2478/raon-2020-0045.

Current management of intrahepatic cholangiocarcinoma: from resection to palliative treatments

Ilenia Bartolini  1 , Matteo Risaliti  1 , Laura Fortuna  1 , Carlotta Agostini  1 , Maria Novella Ringressi  1 , Antonio Taddei  1 , Paolo Muiesan  1   2
Affiliations
Review

Current management of intrahepatic cholangiocarcinoma: from resection to palliative treatments

Ilenia Bartolini et al. Radiol Oncol. .

Abstract

Background Intrahepatic cholangiocarcinoma (ICC) is the second most common liver primary tumour after hepatocellular carcinoma and represents 20% of all the cholangiocarcinomas. Its incidence is increasing and mortality rates are rising. Surgical resection is the only option to cure the disease, despite the high recurrence rates reported to be up to 80%. Intrahepatic recurrences may be still treated with curative intent in a small percentage of the patients. Unfortunately, due to lack of specific symptoms, most patients are diagnosed in a late stage of disease and often unsuitable for resection. Liver transplantation for ICC is still controversial. After the first published poor results, improving outcomes have been reported in highly selected cases, including locally advanced ICC treated with neoadjuvant chemotherapy, when successful in controlling tumour progression. Thus, liver transplantation should be considered a possible option within study protocols. When surgical management is not possible, palliative treatments include chemotherapy, radiotherapy and loco-regional treatments such as radiofrequency ablation, trans-arterial chemoembolization or radioembolization. Conclusions This update on the management of ICC focusses on surgical treatments. Known and potential prognostic factors are highlighted in order to assist in treatment selection.

Keywords: intrahepatic cholangiocarcinoma; liver resection; liver transplantation.

PubMed Disclaimer

References

    1. Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA) Nat Rev Gastroenterol Hepatol. 2016;13:261–80. doi: 10.1038/nrgastro.2016.51. et al. - DOI - PubMed
    1. Spolverato G, Kim Y, Alexandrescu S, Marques HP, Lamelas J, Aldrighetti L. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma following previous curative-intent surgical resection. Ann Surg Oncol. 2016;23:235–43. doi: 10.1245/s10434-015-4642-9. et al. - DOI - PubMed
    1. Valls C, Gumà A, Puig I, Sanchez A, Andía E, Serrano T. Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom Imaging. 2000;25:490–6. doi: 10.1007/s002610000079. et al. - DOI - PubMed
    1. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008;10:77–82. doi: 10.1080/13651820801992641. - DOI - PMC - PubMed
    1. Lunsford KE, Javle M, Heyne K, Shroff RT, Abdel-Wahab R, Gupta N. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series. Lancet Gastroenterol Hepatol. 2018;3:337–48. doi: 10.1016/S2468-1253(18)30045-1. et al. - DOI - PubMed